A Game-Changer for Diabetes: Polymer Delivers Insulin Painlessly Through Skin
November 25, 2025
Brand Name :
Dipentum
Synonyms :
olsalazine
Class :
5-Aminosalicylic Acid Derivatives
Dosage Forms & StrengthsÂ
CapsuleÂ
250 mgÂ
Take maintenance dose of 1 g orally daily in couple of divided doses
Administration.
Consume with meal
Dosing Modifications
Renal impairment
If renal function diminishes while taking medication, stop taking it.
Safety and efficacy not determined Â
For <12 years: Safety and efficacy not determined
For ≥12 years
Starting dose of 250 mg taken orally every six hours and increase by 250 to 500 mg/day, but not exceeding a maximum of 4 g/day
Maintenance dose of usually 2 to 3 g/day, divided into four equal doses every six hours
Dosing Considerations
Not advised in hypertension
Refer to adult dosingÂ
may diminish the metabolism of each other when combined
may diminish the metabolism of each other when combined
may diminish the metabolism of each other when combined
may diminish the metabolism of each other when combined
may diminish the metabolism of each other when combined
may reduce the therapeutic effect
may reduce the therapeutic effect
may reduce the therapeutic effect
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
It may enhance the serum concentration when combined with CYP3A4 Substrates
It may enhance the serum concentration when combined with CYP3A4 Substrates
It may enhance the serum concentration when combined with CYP3A4 Substrates
It may enhance the serum concentration when combined with CYP3A4 Substrates
It may enhance the serum concentration when combined with CYP3A4 Substrates
Actions and SpectrumÂ
olsalazine works by inhibiting the production of prostaglandins and leukotrienes, suppressing the production of inflammatory cytokines and decreasing inflammation.Â
olsalazine’s range of action is restricted to the colon and rectum because it is not absorbed into the bloodstream and has no systemic consequences.Â
Frequency not defined Â
1-10%Â
Arthralgia (4%)Â
Anorexia (1.3%)Â
Dyspepsia (4%)Â
Depression (1.5%)Â
Dizziness (1%)Â
Bloating (1.5%)Â
Joint pain (4%)Â
Upper respiratory infection (1.5%)Â
Nausea/vomiting (6%)Â
Rash/itching (3.6%)Â
Fatigue (1.8%)Â
Headache (5%)Â
>10%Â
Abdominal pain (11%)Â
Diarrhea (17%)Â
Post marketing reportsÂ
Skin and subcutaneous tissue disorders: Angioneurotic edemaÂ
Thoracic, respiratory and mediastinal disorders: Interstitial lung disease, pleurisy/pleuritis, DyspneaÂ
Contraindication/Caution:Â
Contraindication:Â
Caution:Â
Pregnancy warnings:    Â
Pregnancy category: CÂ
Lactation: Excretion into human milk is unknown Â
Pregnancy Categories:        Â
Category A: Studies that were well-controlled and met expectations revealed no risk to the fetus in either the first or second trimester.Â
Category B: There were lack of studies on pregnant women and no evidence of risk to the foetus in animal experiments.  Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.  Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.   Â
Category N: There is no data available for the drug under this category
PharmacologyÂ
Two molecules of 5-aminosalicylic acid (5-ASA) are found in the drug olsalazine, which is joined by an azo bond. olsalazine stays in the colon after consumption and is broken down by bacterial enzymes to release the active component, 5-ASA.Â
PharmacodynamicsÂ
olsalazine’s pharmacodynamics are mostly based on the activity of 5-aminosalicylic acid (5-ASA), which is its active component.Â
5-ASA is an anti-inflammatory drug that reduces inflammation locally in the colon. It is believed to function by preventing the production of leukotrienes and prostaglandins, chemicals involved in the inflammatory process. The generation of inflammatory cytokines, which can aid in the onset of inflammatory bowel disease (IBD), is also suppressed by 5-ASA.Â
PharmacokineticsÂ
Absorption  Â
olsalazine remains in the colon where it is broken down by bacterial enzymes to produce the active component, 5-aminosalicylic acid (5-ASA), as it is not absorbed from the gastrointestinal system. olsalazine has less systemic effects and a lower risk of negative effects because it is not absorbed.Â
DistributionÂ
olsalazine and 5-ASA, the drug’s active component, do not significantly bind to plasma proteins and do not build up in the body. olsalazine does not disperse widely throughout the body since it is not absorbed.Â
MetabolismÂ
In the colon, bacterial enzymes degrade olsalazine to release 5-ASA. 5-ASA is partially metabolized in the liver and eliminated through the urine.Â
Elimination and excretionÂ
olsalazine and 5-ASA are mostly eliminated in the urine. 5-ASA has an elimination half-life of two to three hours.Â
Administration: Â
olsalazine is a medication that can be taken orally as a capsule, usually two to three times per day.Â
Patient information leafletÂ
Generic Name: olsalazineÂ
Why do we use olsalazine?Â
olsalazine is a drug mostly used to treat mild to moderate ulcerative colitis, a form of inflammatory bowel disease that damages the lining of the colon and rectum.Â